secwatch.observer — SEC 8-K summary
======================================

Issuer:     Guardant Health, Inc. (GH)
CIK:        0001576280
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001576280-23-000059
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Guardant Health Q1 revenue up 34% to $128.7M; raises FY2023 guidance to $535-545M
--------------------------------------------------------------------------------

- Revenue $128.7M (+34% YoY); clinical tests 39,100 (+45%), biopharma tests 6,150 (+21%).
- Net loss $133.5M ($1.30/share) vs $123.2M ($1.21) prior year; non-GAAP net loss $108.5M ($1.06).
- Gross margin 59% (down from 67%) on mix shift; operating expenses $209.7M (+12%).
- FY2023 revenue guidance raised to $535-545M (prev $525-540M); expects FCF outflow ~$350M.
- Appointed Ines Dahne-Steuber COO and promoted Darya Chudova CTO; Shield CRC screening PMA under FDA review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576280/000157628023000059/0001576280-23-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576280/000157628023000059/gh-20230509.htm
  HTML page:      https://secwatch.observer/filing/0001576280-23-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer